Comparison of mean B(a)P-DNA adducts by treatment group, gender, and GSTM1
. | Unadjusted geometric mean B(a)P-DNA adducts . | . | . | . | . | Adjusted by pretreatment B(a)P-DNA adducts and pretreatment cotinine . | . | . | . | . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Treatment . | Placebo . | Treatment/placebo . | 95% Confidence interval . | P . | Treatment . | Placebo . | Treatment/placebo . | 95% Confidence interval . | P . | ||||||||
All subjects with 15 months follow-up | 0.39 (n = 83) | 0.45 (n = 93) | 0.86 | 0.69-1.08 | 0.20 | 0.39 | 0.45 | 0.86 | 0.69-1.08 | 0.19 | ||||||||
Women | 0.32 (n = 37) | 0.46 (n = 43) | 0.70 | 0.51-0.97 | 0.04* | 0.32 | 0.46 | 0.69 | 0.50-0.95 | 0.03 | ||||||||
Men | 0.46 (n = 46) | 0.45 (n = 50) | 1.02 | 0.75-1.38 | 0.92 | 0.46 | 0.46 | 1.00 | 0.74-1.36 | 0.98 | ||||||||
GSTM normal | 0.43 (n = 52) | 0.50 (n = 62) | 0.86 | 0.64-1.15 | 0.30 | 0.43 | 0.49 | 0.87 | 0.65-1.17 | 0.36 | ||||||||
GSTM null | 0.34 (n = 31) | 0.38 (n = 31) | 0.90 | 0.65-1.25 | 0.54 | 0.35 | 0.37 | 0.94 | 0.66-1.32 | 0.71 | ||||||||
Women: GSTM normal | 0.35 (n = 28) | 0.47 (n = 29) | 0.74 | 0.49-1.12 | 0.16 | 0.34 | 0.47 | 0.73 | 0.48-1.10 | 0.14 | ||||||||
Women: GSTM null | 0.25 (n = 9) | 0.43 (n = 14) | 0.58 | 0.37-0.93 | 0.04* | 0.25 | 0.44 | 0.57 | 0.35-0.94 | 0.04* | ||||||||
Men: GSTM normal | 0.54 (n = 24) | 0.53 (n = 33) | 1.03 | 0.69-1.55 | 0.88 | 0.56 | 0.52 | 1.07 | 0.72-1.61 | 0.73 | ||||||||
Men: GSTM null | 0.38 (n = 22) | 0.34 (n = 17) | 1.14 | 0.73-1.78 | 0.57 | 0.40 | 0.32 | 1.23 | 0.76-2.00 | 0.40 |
. | Unadjusted geometric mean B(a)P-DNA adducts . | . | . | . | . | Adjusted by pretreatment B(a)P-DNA adducts and pretreatment cotinine . | . | . | . | . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Treatment . | Placebo . | Treatment/placebo . | 95% Confidence interval . | P . | Treatment . | Placebo . | Treatment/placebo . | 95% Confidence interval . | P . | ||||||||
All subjects with 15 months follow-up | 0.39 (n = 83) | 0.45 (n = 93) | 0.86 | 0.69-1.08 | 0.20 | 0.39 | 0.45 | 0.86 | 0.69-1.08 | 0.19 | ||||||||
Women | 0.32 (n = 37) | 0.46 (n = 43) | 0.70 | 0.51-0.97 | 0.04* | 0.32 | 0.46 | 0.69 | 0.50-0.95 | 0.03 | ||||||||
Men | 0.46 (n = 46) | 0.45 (n = 50) | 1.02 | 0.75-1.38 | 0.92 | 0.46 | 0.46 | 1.00 | 0.74-1.36 | 0.98 | ||||||||
GSTM normal | 0.43 (n = 52) | 0.50 (n = 62) | 0.86 | 0.64-1.15 | 0.30 | 0.43 | 0.49 | 0.87 | 0.65-1.17 | 0.36 | ||||||||
GSTM null | 0.34 (n = 31) | 0.38 (n = 31) | 0.90 | 0.65-1.25 | 0.54 | 0.35 | 0.37 | 0.94 | 0.66-1.32 | 0.71 | ||||||||
Women: GSTM normal | 0.35 (n = 28) | 0.47 (n = 29) | 0.74 | 0.49-1.12 | 0.16 | 0.34 | 0.47 | 0.73 | 0.48-1.10 | 0.14 | ||||||||
Women: GSTM null | 0.25 (n = 9) | 0.43 (n = 14) | 0.58 | 0.37-0.93 | 0.04* | 0.25 | 0.44 | 0.57 | 0.35-0.94 | 0.04* | ||||||||
Men: GSTM normal | 0.54 (n = 24) | 0.53 (n = 33) | 1.03 | 0.69-1.55 | 0.88 | 0.56 | 0.52 | 1.07 | 0.72-1.61 | 0.73 | ||||||||
Men: GSTM null | 0.38 (n = 22) | 0.34 (n = 17) | 1.14 | 0.73-1.78 | 0.57 | 0.40 | 0.32 | 1.23 | 0.76-2.00 | 0.40 |
P < 0.05.